Tags

Type your tag names separated by a space and hit enter

Hormonal contraceptive use and risk of pancreatic cancer-A cohort study among premenopausal women.
PLoS One 2018; 13(10):e0206358Plos

Abstract

IMPORTANCE

The association between the use of hormonal contraceptive and pancreatic cancer among premenopausal women has until now been unclear. This is the first study to investigate the risk of pancreatic cancer in pre-menopausal women.

OBJECTIVE

To determine whether hormonal contraception increases the risk of developing pancreatic cancer in pre-menopausal women.

DESIGN

A nationwide prospective cohort study followed all women in Denmark in the age range of 15-49 years without previous cancer or venous thrombosis from 1995 to 2014. The Danish National Prescription Registry provided individually updated exposure information on use of hormonal contraception. The Danish Cancer Registry provided cancer diagnoses, and the Danish National Patient Register containing clinical diagnoses and surgical codes at discharge from public and private hospitals.

SETTING

Population-based cohort study.

PARTICIPANTS

All women living in Denmark aged 15-49 years at January 1st, 1995, and those subsequently reaching age 15 years up to December 31st, 2014 were eligible for the study.

RESULTS

Among 1.9 million women who were followed on average for 11.4 years, 235 pancreatic cancers occurred. Compared to never users, ever users of any type of hormonal contraception had a relative risk (RR) of pancreatic cancer of 0.90 (95% confidence interval (CI) 0.68-1.19). No overall association between duration of hormonal contraceptive use and pancreatic cancer risk was found. Neither was long-term use of hormonal contraception associated with pancreas cancer, RR 0.83 (95% CI 0.47-1.50). The risk did not vary between users of combined and progestogen-only products. All models were adjusted for age, completed or ongoing education, polycystic ovary syndrome, endometriosis and among parous women; parity, age at first birth, smoking and body mass index.

CONCLUSIONS AND RELEVANCE

Compared to never users the risk of pancreatic cancer is not significantly higher among current and recent users of contemporary hormonal contraception and does not vary between users of combined and progestogen-only products. In conclusion, our study suggests no risk of pancreatic cancer with use of any type of hormonal contraception.

Authors+Show Affiliations

Copenhagen University Hospital, The Juliane Marie Centre, Department of Gynecology, Copenhagen, Denmark.Copenhagen University Hospital, The Juliane Marie Centre, Department of Gynecology, Copenhagen, Denmark.Copenhagen University Hospital, The Juliane Marie Centre, Department of Gynecology, Copenhagen, Denmark.Academic Primary Care, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom.Academic Primary Care, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom.Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom.Copenhagen University Hospital, The Juliane Marie Centre, Department of Gynecology, Copenhagen, Denmark.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30376560

Citation

Butt, Sedrah Arif, et al. "Hormonal Contraceptive Use and Risk of Pancreatic cancer-A Cohort Study Among Premenopausal Women." PloS One, vol. 13, no. 10, 2018, pp. e0206358.
Butt SA, Lidegaardi Ø, Skovlund C, et al. Hormonal contraceptive use and risk of pancreatic cancer-A cohort study among premenopausal women. PLoS ONE. 2018;13(10):e0206358.
Butt, S. A., Lidegaardi, Ø., Skovlund, C., Hannaford, P. C., Iversen, L., Fielding, S., & Mørch, L. S. (2018). Hormonal contraceptive use and risk of pancreatic cancer-A cohort study among premenopausal women. PloS One, 13(10), pp. e0206358. doi:10.1371/journal.pone.0206358.
Butt SA, et al. Hormonal Contraceptive Use and Risk of Pancreatic cancer-A Cohort Study Among Premenopausal Women. PLoS ONE. 2018;13(10):e0206358. PubMed PMID: 30376560.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hormonal contraceptive use and risk of pancreatic cancer-A cohort study among premenopausal women. AU - Butt,Sedrah Arif, AU - Lidegaardi,Øjvind, AU - Skovlund,Charlotte, AU - Hannaford,Philip C, AU - Iversen,Lisa, AU - Fielding,Shona, AU - Mørch,Lina Steinrud, Y1 - 2018/10/30/ PY - 2018/02/15/received PY - 2018/10/11/accepted PY - 2018/10/31/entrez PY - 2018/10/31/pubmed PY - 2019/4/4/medline SP - e0206358 EP - e0206358 JF - PloS one JO - PLoS ONE VL - 13 IS - 10 N2 - IMPORTANCE: The association between the use of hormonal contraceptive and pancreatic cancer among premenopausal women has until now been unclear. This is the first study to investigate the risk of pancreatic cancer in pre-menopausal women. OBJECTIVE: To determine whether hormonal contraception increases the risk of developing pancreatic cancer in pre-menopausal women. DESIGN: A nationwide prospective cohort study followed all women in Denmark in the age range of 15-49 years without previous cancer or venous thrombosis from 1995 to 2014. The Danish National Prescription Registry provided individually updated exposure information on use of hormonal contraception. The Danish Cancer Registry provided cancer diagnoses, and the Danish National Patient Register containing clinical diagnoses and surgical codes at discharge from public and private hospitals. SETTING: Population-based cohort study. PARTICIPANTS: All women living in Denmark aged 15-49 years at January 1st, 1995, and those subsequently reaching age 15 years up to December 31st, 2014 were eligible for the study. RESULTS: Among 1.9 million women who were followed on average for 11.4 years, 235 pancreatic cancers occurred. Compared to never users, ever users of any type of hormonal contraception had a relative risk (RR) of pancreatic cancer of 0.90 (95% confidence interval (CI) 0.68-1.19). No overall association between duration of hormonal contraceptive use and pancreatic cancer risk was found. Neither was long-term use of hormonal contraception associated with pancreas cancer, RR 0.83 (95% CI 0.47-1.50). The risk did not vary between users of combined and progestogen-only products. All models were adjusted for age, completed or ongoing education, polycystic ovary syndrome, endometriosis and among parous women; parity, age at first birth, smoking and body mass index. CONCLUSIONS AND RELEVANCE: Compared to never users the risk of pancreatic cancer is not significantly higher among current and recent users of contemporary hormonal contraception and does not vary between users of combined and progestogen-only products. In conclusion, our study suggests no risk of pancreatic cancer with use of any type of hormonal contraception. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/30376560/Hormonal_contraceptive_use_and_risk_of_pancreatic_cancer_A_cohort_study_among_premenopausal_women_ L2 - http://dx.plos.org/10.1371/journal.pone.0206358 DB - PRIME DP - Unbound Medicine ER -